Objective We performed a scoping review of randomised clinical trials (RCTs) assessing pharmacological therapies for the initial management of lupus nephritis (LN), focusing on study design, included ...

Objective Anifrolumab is a fully human immunoglobulin G 1 κ monoclonal antibody specific for subunit 1 of the type I interferon (IFN) α receptor. In a phase IIb study of adults with moderate to severe ...

Objective To explore the potential associations between high-density lipoprotein (HDL) levels and inflammasome components in the context of systemic lupus erythematosus (SLE).Methods A cross-sectional ...

Objective Black people in the USA have a higher incidence and severity of SLE and worse outcomes, yet they are significantly under-represented in SLE clinical trials. We assessed racial differences in ...

Objective To examine the efficacy and safety of telitacicept in the treatment of patients with SLE in everyday clinical practice.Methods Seventy-two patients with active SLE who received telitacicept ...

Objective In phase II and III trials, anifrolumab, a human monoclonal antibody that binds type I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We evaluated ...

A lupus journal publishing basic, clinical, translational and epidemiological studies on all aspects of lupus and related diseases. An official journal of Lupus Foundation of America.

Objective Quinolinic acid (QA), a kynurenine (KYN)/tryptophan (TRP) pathway metabolite, is an N-methyl-D-aspartate receptor agonist that can produce excitotoxic neuron damage. Type I and II ...

Objectives Even in a lupus low disease activity state (LLDAS), many patients with SLE continue to face residual symptoms and disease burden. We aimed to evaluate the quality of life, activity ...

Objective SLE is a chronic autoimmune disease with immune complex deposition in various organs, causing inflammation. The Systemic Lupus Erythematosus Disease Activity Index 2000 assesses disease ...

Objective Punch biopsy, a standard diagnostic procedure for patients with cutaneous lupus erythematosus (CLE) carries an infection risk, is invasive, uncomfortable and potentially scarring, and ...

Objectives To achieve consensus on domains of active disease for inclusion in a novel outcome measure for SLE randomised controlled trials (RCTs), the Treatment Response Measure for SLE ...